Nasdaq exas.

EXAS missed the consensus earnings per share in the 1st calendar quarter of 2020 by -5.26%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for EXAS is -92.27 vs. an ...

Nasdaq exas. Things To Know About Nasdaq exas.

In trading on Wednesday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $73.14, changing hands as low as $72.66 per share. EXACT Sciences Corp. shares ...A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...

As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.53%. At the same ...Exact Sciences Corp (NASDAQ:EXAS), a leading global cancer diagnostics company, has recently released its SEC 10-Q filing for the quarter ended September 30, 2023. The company has shown ...

Exact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...

Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment ...

First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...

... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …WebJul 31, 2023 · EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ... At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new August 26th contracts and identified one put and one call contract of particular interest ...Exact Sciences ( EXAS 8.39%) can't claim all the credit, but the non-invasive cancer tests that it markets play an important role. The company's cancer tests screened around 4 million people in ...Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...In trading on Wednesday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $73.14, changing hands as low as $72.66 per share. EXACT Sciences Corp. shares ...15.19M. 127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed …Web

Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive").Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... Exact Sciences Corporation (NASDAQ:EXAS) is an extremely timely and compelling short, with an imminent catalyst that we believe will cause shares to plummet as much as 75% in the near future. EXAS ...

Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...

Importantly, Exact Sciences Corporation (NASDAQ:EXAS) does carry debt. But the more important question is: how much risk is that debt creating? Why Does Debt Bring Risk? Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take ...Exact Sciences (NASDAQ: EXAS) stock had tumbled nearly 27% over the last six months. Yet the company reported strong third-quarter financial results on Nov. 1 and has multiple strong positive ...EXACT Sciences Corporation (NASDAQ: EXAS) was in 40 hedge funds' portfolios at the end of December. The all time high for this statistic is 43. EXAS has seen an increase in hedge fund sentiment ...The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Analyst's Opinion · Consensus Rating. Exact Sciences has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to analysts' ...Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...

EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).

Oct 13, 2022 01:52PM EDT. Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 2nd expiration. At Stock Options Channel, our YieldBoost formula ...Nov 27, 2023 · Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.? Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.WebFintel reports that on May 10, 2023, Credit Suisse maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...15.19M. 127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed …WebExact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. Exact Sciences Co. (NASDAQ:EXAS) Insider Sells $864,835.43 in Stock marketbeat.com - October 13 at 8:39 PM: Baillie Gifford & Co. Sells 215,265 Shares of Exact Sciences Co. (NASDAQ:EXAS) marketbeat.com - October 12 at 3:16 PM: Exact Sciences upgraded at Piper Sandler on compelling entry point seekingalpha.com - October 12 at …Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...Instagram:https://instagram. learn crypto tradingbest bank stocks to buysaphire pakistantruck tesla 01 Nov, 2023, 06:00 ET. MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that company ...Exact Sciences EXAS continues to make significant progress with its Cologuard test. The integration of PreventionGenetics also buoys optimism. Escalating expenses, its sole reliance on Cologuard ... nasdaq ticker symbolseaton corporation stock Exact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $11.574 billion. Artisan Small Cap Fund made the following comment about Exact …WebExact Sciences Announces Fourth Quarter 2020 Results. MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. best investments on start engine Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.